Biotechnology Value Fund L P - Net Worth and Insider Trading

Biotechnology Value Fund L P Net Worth

The estimated net worth of Biotechnology Value Fund L P is at least $895 Million dollars as of 2024-04-25. Biotechnology Value Fund L P is the of Kymera Therapeutics Inc and owns about 5,054,898 shares of Kymera Therapeutics Inc (KYMR) stock worth over $169 Million. Biotechnology Value Fund L P is the of Cullinan Therapeutics Inc and owns about 7,415,823 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $143 Million. Biotechnology Value Fund L P is also the of Xenon Pharmaceuticals Inc and owns about 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $122 Million. Besides these, Biotechnology Value Fund L P also holds XOMA Corp (XOMA) , Olema Pharmaceuticals inc (OLMA) , ChemoCentryx Inc (CCXI) , Third Harmonic Bio Inc (THRD) , Alpine Immune Sciences Inc (ALPN) , Repare Therapeutics Inc (RPTX) , Cytokinetics Inc (CYTK) , CTI BioPharma Corp (CTIC) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Eledon Pharmaceuticals Inc (ELDN) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , Concert Pharmaceuticals Inc (CNCE) , GlycoMimetics Inc (GLYC) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) . Details can be seen in Biotechnology Value Fund L P's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Biotechnology Value Fund L P has not made any transactions after 2023-12-18 and currently still holds the listed stock(s).

Transaction Summary of Biotechnology Value Fund L P

To

Biotechnology Value Fund L P Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Biotechnology Value Fund L P owns 52 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Corp (XOMA) among others .

Click here to see the complete history of Biotechnology Value Fund L P’s form 4 insider trades.

Insider Ownership Summary of Biotechnology Value Fund L P

Ticker Comapny Transaction Date Type of Owner
FPRX Five Prime Therapeutics Inc 2020-11-11 10 percent owner
ELDN Eledon Pharmaceuticals Inc 2023-05-05 other: See Explanation of Responses
XOMA XOMA Corp 2023-01-06 other: See Explanation of Responses
MRUS Merus NV 2021-10-08 other: See Explanation of Responses
KYMR Kymera Therapeutics Inc 2023-11-03 other: See Explanation of Responses
PRNB Principia Biopharma Inc 2020-08-18 other: See Explanation of Responses
IDYA IDEAYA Biosciences Inc 2021-02-02 other: See Explanation of Responses
CALA Calithera Biosciences Inc 2020-05-21 other: See Explanation of Responses
CTIC CTI BioPharma Corp 2022-08-09 other: See Explanation of Responses
CYTK Cytokinetics Inc 2020-12-09 other: See Explanation of Responses
PIRS Pieris Pharmaceuticals Inc 2019-09-06 other: See Explanation of Responses
GLYC GlycoMimetics Inc 2020-11-04 other: See Explanation of Responses
CNCE Concert Pharmaceuticals Inc 2019-06-10 other: See Explanation of Responses
INFIQ Infinity Pharmaceuticals Inc 2021-02-11 other: See Explanation of Responses
IMDZ Immune Design Corp 2018-12-04 other: See Explanation of Responses
SNDX Syndax Pharmaceuticals Inc 2017-11-28 other: See Explanation of Responses
ARQL Arqule Inc 2018-05-30 other: See Explanation of Responses
XENE Xenon Pharmaceuticals Inc 2017-08-15 other: See Explanation of Responses
RGLS Regulus Therapeutics Inc 2017-11-17 other: See Explanation of Responses
CAPS Capstone Holding Corp 2017-07-14 10 percent owner & other: Direct Beneficial Owner
ALPN Alpine Immune Sciences Inc 2017-06-20 other: See Explanation of Responses
CASC Cascadian Therapeutics Inc 2016-06-23 10 percent owner
CCXI ChemoCentryx Inc 2015-11-04 other: See Explanation of Responses
CBIO Catalyst Biosciences Inc 2009-07-09 other: Direct Beneficial Owner
LGND Ligand Pharmaceuticals Inc 2008-11-06 10 percent owner & other: Direct Beneficial Owners
RGDO Regado Biosciences Inc 2014-03-21 other: See Explanation of Responses
PTN Palatin Technologies Inc 2011-10-05 other: See Explanation of Responses
RIGL Rigel Pharmaceuticals Inc 2013-05-01 other: See Explanation of Responses
NBIX Neurocrine Biosciences Inc 2008-02-20 10 percent owner & other: Direct Beneficial Owner
EPRSQ EPIRUS Biopharmaceuticals Inc 2009-12-22 other: Direct Beneficial Owner
MNOV MediciNova Inc 2009-12-18 10 percent owner
NTII Neurobiological Technologies Inc 2009-10-21 other: Direct Beneficial Owner
DVAX Dynavax Technologies Corp 2008-10-23 10 percent owner & other: Indirect Beneficial Owners
RGEN Repligen Corp 2009-05-15 10 percent owner & other: Group Member
CRIS Curis Inc 2009-02-03 10 percent owner & other: Indirect Beneficial Owners
AOLS Aeolus Pharmaceuticals Inc 2006-06-06 10 percent owner & other: Indirect Beneficial Owner
AMAG AMAG Pharmaceuticals Inc 2006-01-12 other: Direct Beneficial Owner
ARNA Arena Pharmaceuticals Inc 2004-07-07 other: Direct Beneficial Owner
BCRX BioCryst Pharmaceuticals Inc 2003-10-27 other: Direct Beneficial Owner
XOMAO.PFD XOMA Corp 2017-02-10 other: See Explanation of Responses
CTMX CytomX Therapeutics Inc 2020-12-18 other: See Explanation of Responses
VSTM Verastem Inc 2022-01-25 other: See Explanation of Responses
RAIN Rain Oncology Inc 2022-11-08 other: See Explanation of Responses
OLMA Olema Pharmaceuticals inc 2023-09-12 10 percent owner
CGEM Cullinan Oncology Inc 2022-06-01 other: See Explanation of Responses
RPTX Repare Therapeutics Inc 2023-11-16 other: See Explanation of Responses
MLTX MoonLake Immunotherapeutics 2022-04-05 director & 10 percent owner
FDMT 4D Molecular Therapeutics Inc 2022-06-16 other: See Explanation of Responses
EPIX ESSA Pharma Inc 2022-07-11 10 percent owner
THRD Third Harmonic Bio Inc 2022-12-20 other: See Explanation of Responses
GPCR Structure Therapeutics Inc 2023-02-03 other: See Explanation of Responses
PNT POINT Biopharma Global Inc 2023-12-18 other: See Explanation of Responses

Biotechnology Value Fund L P Latest Holdings Summary

Biotechnology Value Fund L P currently owns a total of 25 stocks. Among these stocks, Biotechnology Value Fund L P owns 5,054,898 shares of Kymera Therapeutics Inc (KYMR) as of November 3, 2023, with a value of $169 Million and a weighting of 18.84%. Biotechnology Value Fund L P owns 7,415,823 shares of Cullinan Therapeutics Inc (CGEM) as of June 1, 2022, with a value of $143 Million and a weighting of 15.95%. Biotechnology Value Fund L P also owns 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) as of August 15, 2017, with a value of $122 Million and a weighting of 13.67%. The other 22 stocks XOMA Corp (XOMA) , Olema Pharmaceuticals inc (OLMA) , ChemoCentryx Inc (CCXI) , Third Harmonic Bio Inc (THRD) , Alpine Immune Sciences Inc (ALPN) , Repare Therapeutics Inc (RPTX) , Cytokinetics Inc (CYTK) , CTI BioPharma Corp (CTIC) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Eledon Pharmaceuticals Inc (ELDN) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , Concert Pharmaceuticals Inc (CNCE) , GlycoMimetics Inc (GLYC) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) have a combined weighting of 51.54% among all his current holdings.

Latest Holdings of Biotechnology Value Fund L P

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KYMR Kymera Therapeutics Inc 2023-11-03 5,054,898 33.35 168,580,848
CGEM Cullinan Therapeutics Inc 2022-06-01 7,415,823 19.25 142,754,593
XENE Xenon Pharmaceuticals Inc 2017-08-15 3,049,626 40.10 122,290,003
XOMA XOMA Corp 2023-01-06 3,645,542 25.36 92,450,945
OLMA Olema Pharmaceuticals inc 2023-09-12 8,897,173 9.83 87,459,211
CCXI ChemoCentryx Inc 2015-11-04 1,251,914 51.99 65,087,009
THRD Third Harmonic Bio Inc 2022-12-20 4,338,167 10.46 45,377,227
ALPN Alpine Immune Sciences Inc 2017-06-20 507,040 64.62 32,764,925
RPTX Repare Therapeutics Inc 2023-11-16 10,166,943 3.15 32,025,870
CYTK Cytokinetics Inc 2020-12-09 463,244 64.80 30,018,211
CTIC CTI BioPharma Corp 2022-08-09 2,271,791 9.09 20,650,580
ARQL Arqule Inc 2018-05-30 771,305 20.00 15,426,100
MRUS Merus NV 2021-10-08 232,747 44.93 10,457,323
IDYA IDEAYA Biosciences Inc 2021-02-02 233,150 38.62 9,004,253
ELDN Eledon Pharmaceuticals Inc 2023-05-05 4,288,005 2.02 8,661,770
RAIN Rain Oncology Inc 2022-11-08 3,288,186 1.21 3,978,705
FPRX Five Prime Therapeutics Inc 2020-11-11 81,263 38.00 3,087,994
IMDZ Immune Design Corp 2018-12-04 370,391 5.85 2,166,787
CNCE Concert Pharmaceuticals Inc 2019-06-10 169,589 8.37 1,419,460
GLYC GlycoMimetics Inc 2020-11-04 630,453 1.71 1,078,075
PIRS Pieris Pharmaceuticals Inc 2019-09-06 3,927 11.60 45,553
CAPS Capstone Holding Corp 2017-07-14 2,268 7.00 15,876
CALA Calithera Biosciences Inc 2020-05-21 24,022 0.02 480
INFIQ Infinity Pharmaceuticals Inc 2021-02-11 534,847 0.00 53
PNT POINT Biopharma Global Inc 2023-12-18 0 12.50 0

Holding Weightings of Biotechnology Value Fund L P


Biotechnology Value Fund L P Form 4 Trading Tracker

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 8 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 8 buys and 0 sells. The most-recent trade in Kymera Therapeutics Inc is the acquisition of 414,105 shares on November 3, 2023, which cost Biotechnology Value Fund L P around $5 Million.

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 3 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Cullinan Therapeutics Inc is the acquisition of 751,396 shares on June 1, 2022, which cost Biotechnology Value Fund L P around $8 Million.

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 0 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years. The most-recent trade in Xenon Pharmaceuticals Inc is the acquisition of 60,202 shares on August 15, 2017, which cost Biotechnology Value Fund L P around $157,127.

More details on Biotechnology Value Fund L P's insider transactions can be found in the Insider Trading History of Biotechnology Value Fund L P table.

Insider Trading History of Biotechnology Value Fund L P

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Biotechnology Value Fund L P Trading Performance

GuruFocus tracks the stock performance after each of Biotechnology Value Fund L P's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Biotechnology Value Fund L P is 30.17%. GuruFocus also compares Biotechnology Value Fund L P's trading performance to market benchmark return within the same time period. The performance of stocks bought by Biotechnology Value Fund L P within 3 months outperforms 55 times out of 106 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Biotechnology Value Fund L P's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Biotechnology Value Fund L P

Average Return

44.18%

Average return per transaction

Outperforming Transactions

62%

61 out of 98 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 11.16 30.17 33.81 44.18 4.46 5.11
Relative Return to S&P 500(%) 10.08 25.65 27.09 28.43 -6.56 -6.7

Biotechnology Value Fund L P Ownership Network

Ownership Network List of Biotechnology Value Fund L P

No Data

Ownership Network Relation of Biotechnology Value Fund L P


Biotechnology Value Fund L P Owned Company Details

What does Five Prime Therapeutics Inc do?

Who are the key executives at Five Prime Therapeutics Inc?

Biotechnology Value Fund L P is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Bvf Partners L P/il , 10 percent owner Bvf Inc/il , and other: See Explanation of Responses Biotechnology Value Fund Ii Lp .

Five Prime Therapeutics Inc (FPRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Five Prime Therapeutics Inc Insider Transactions

No Available Data

Biotechnology Value Fund L P Mailing Address

Above is the net worth, insider trading, and ownership report for Biotechnology Value Fund L P. You might contact Biotechnology Value Fund L P via mailing address: 44 Montgomery Street, 40th Fl, San Francisco Ca 94104.

Discussions on Biotechnology Value Fund L P

No discussions yet.